BPC-157 (body protection compound-157, a synthetic peptide and synthetic pentadecapeptide) is a 15-amino-acid sequence derived from gastric juice with potent anti-inflammatory and injury recovery properties. Used in peptide therapy research, it has been studied across tendon repair, gastrointestinal healing, muscle recovery, and bone regeneration — organized by research timeline. For the full compound profile, see the BPC-157 compound page. For human trial data, see BPC-157 Human Trials.
Early research subjects typically report reduced localized inflammation and pain at injury sites within the first 1–2 weeks. Nitric oxide upregulation begins within 48–72 hours of administration. GI subjects report improved mucosal comfort. Tendon and ligament subjects note reduced morning stiffness.
BPC-157 upregulates VEGF (vascular endothelial growth factor) and promotes new blood vessel formation at injury sites. This is the primary mechanism behind accelerated tissue repair. Subjects with chronic tendon injuries typically report measurable improvement in range of motion by week 4.
Collagen synthesis increases significantly during this phase. Tendon, ligament, and muscle tissue show organized fiber deposition rather than scar tissue formation. GI subjects with SIBO or leaky gut typically show the most pronounced improvements, with mucosal integrity markers normalizing.
By week 12, most research subjects with acute injuries report near-complete functional restoration. Chronic injury subjects show 60–80% improvement in pain scores. GI subjects typically report sustained symptom resolution. The 12-week endpoint is the most commonly used assessment point in published BPC-157 research.
| Application | Before | After | Timeframe |
|---|---|---|---|
| Tendon & Ligament Injuries | Pain, limited ROM, chronic inflammation | Reduced pain, improved ROM, organized collagen deposition | 4–12 weeks |
| Muscle Tears | Structural damage, reduced strength, inflammation | Accelerated fiber regeneration, restored strength | 3–8 weeks |
| GI / SIBO | Mucosal damage, dysbiosis, permeability | Improved mucosal integrity, reduced symptoms | 4–8 weeks |
| Bone Fractures | Slow callus formation, pain | Accelerated callus formation, faster union | 6–12 weeks |
| Nerve Damage | Impaired conduction, pain, weakness | Improved nerve regeneration markers | 8–16 weeks |
Most research subjects report early effects (reduced inflammation, improved comfort) within 1–2 weeks. Structural tissue repair peaks at 4–8 weeks. Full functional restoration in acute injuries typically occurs by week 12. Chronic injuries may require 16–24 weeks of research protocols.
Published animal studies show BPC-157 accelerates tendon healing by 40–60% compared to controls. Results include superior collagen organization and reduced scar tissue formation. Human research subjects with chronic tendinopathy typically report 60–80% improvement in pain and function scores by week 12.
BPC-157 was originally isolated from gastric juice and has the strongest published evidence base for GI applications. Research shows it promotes mucosal healing and reduces intestinal permeability. It also improves SIBO markers. GI subjects typically see the most rapid results, often within 4–6 weeks.
Most published research uses 250–500 mcg/day administered subcutaneously or intramuscularly. Some GI research uses oral administration at 250–500 mcg/day. The optimal dose depends on the research application — tendon/muscle repair typically uses 200–400 mcg/day, while GI research often uses 250–500 mcg/day.
Most published research protocols run 4–12 weeks. For acute injuries, 4–6 weeks is often sufficient. For chronic conditions or structural repair, 8–12 weeks is more typical. Some researchers run 12–16 week protocols for complex injuries or GI conditions.
Purgo Labs provides pharmaceutical-grade BPC-157 with third-party COAs. Use code HEALTH for 20% off your first order.
Buy BPC-157 at Purgo Labs